Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 7, 2014; 20(29): 10183-10192
Published online Aug 7, 2014. doi: 10.3748/wjg.v20.i29.10183
Published online Aug 7, 2014. doi: 10.3748/wjg.v20.i29.10183
Transthoracic vs transhiatal surgery for cancer of the esophagogastric junction: A meta-analysis
Ming-Tian Wei, Yuan-Chuan Zhang, Xiang-Bing Deng, Ting-Han Yang, Ya-Zhou He, Zi-Qiang Wang, Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Wei MT and Wang ZQ designed the research; Wang ZQ provided supervision; Wei MT and He YZ performed the research; Deng XB and Yang TH performed a literature search and collected the data; Wei MT and Zhang YC analyzed the data and wrote the paper.
Supported by National Natural Science Foundation of China, No. 81172373
Correspondence to: Zi-Qiang Wang, Professor, Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Chengdu 610041, Sichuan Province, China. wangzqzyh@163.com
Telephone: +86-28-85422480 Fax: +86-28-81654035
Received: November 20, 2013
Revised: February 13, 2014
Accepted: March 5, 2014
Published online: August 7, 2014
Processing time: 260 Days and 0.8 Hours
Revised: February 13, 2014
Accepted: March 5, 2014
Published online: August 7, 2014
Processing time: 260 Days and 0.8 Hours
Core Tip
Core tip: Surgical resection is the optimum therapy for cancer of the esophagogastric junction, and the transthoracic and transhiatal approaches are the two major surgical approaches used worldwide. However, considerable debate exists on the superior benefits of the two approaches regarding their efficacy and safety. We conducted this meta-analysis to address the issue. The results indicated a shorter hospital stay, lower 30-d hospital mortality and decreased pulmonary complications with the transhiatal approach compared with the transthoracic approach. Moreover, a potential survival benefit was achieved for type III tumors using the transhiatal approach.